Phaseline

Companies › Upstream Bio

Upstream Bio: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Respiratory; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Verekitug (UPB-101)–Phase 2Severe Asthma; Chronic Obstructive Pulmonary DiseaseSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06966479Verekitug (UPB-101)Phase 2Severe AsthmaRespiratorySep 2027
NCT06981078Verekitug (UPB-101)Phase 2Chronic Obstructive Pulmonary DiseaseRespiratoryOct 2027

From the company's SEC filings

Cash and short-term investments of $207m on 2026-09-30; operating cash outflow about $185m a year; runway about 14 months at that burn, to Nov 2027; 2 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Connect Biopharm Aqualung Therapeutics PPD Development, LP Rein Therapeutics Shanghai Mabgeek Biotech.Co.Ltd

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.